Condition: Relapsed Advanced Lymphomas · Sponsor: Aurigene Discovery Technologies Limited
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
This description comes directly from the study's public registry record.
Suchit D Kumbhare · +91- 8104730078 · suchit_k@aurigene.com
Suresh O · +91-9866225593 · suresh_o@aurigene.com
Always discuss trial participation with your own doctor first.
| Sir Sayajirao General Hospital (SSG) | Vadodara, Gujarat, India | Active Not Recruiting |
| National Cancer Institute , All India Institute of Medical Sciences | Jhajjar, Haryana, India | Recruiting |
| Health Care Global Enterprises | Bangalore, Karnataka, India | Active Not Recruiting |
| Srinivasam Cancer Care Multi Speciality Hospitals India Pvt Ltd. , Bangalore 560072. | Bangalore, Karnataka, India | Recruiting |
| Jeevan Amrut Hematology Center, Aurangabad | Aurangabad, Maharashtra, India | Recruiting |
| HCG Cancer Centre | Nagpur, Maharashtra, India | Recruiting |
| Sahyadri Hospital Private Limited | Pune, Maharashtra, India | Recruiting |
| Novo Solitaire Care | Pune, Maharashtra, India | Recruiting |
| Armed Forces Medical College | Pune, Maharashtra, India | Not Yet Recruiting |
| Onco Life Cancer, Centre, Satara | Satara, Maharashtra, India | Recruiting |
| Sunact Cancer Institute Pvt. Ltd | Thane, Maharashtra, India | Recruiting |
| Siddharth Gupta Memorial Hospital, | Wardha, Maharashtra, India | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06755450